article thumbnail

The Winners of the 2019 Xconomy Awards San Diego Are…

Xconomy

The nominees and finalists for the first-ever Xconomy Awards San Diego were an impressive bunch, making it tough for our judges and the editors to pick the winners. After much discussion and debate, we decided that these winners represent the best of the San Diego life sciences and healthtech community.

San Diego 107
article thumbnail

San Diego Life Sciences Roundup: MedCrypt, LunaDNA, Dynacure & More

Xconomy

Let’s catch up with the latest life sciences news in San Diego. “Patient data privacy has long been a concern, but the healthcare industry is just beginning to address patient safety risks presented by internet-connected healthcare technology,” Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

San Diego Life Sciences Roundup: MEI Pharma, Turning Point, & More

Xconomy

It was a relatively quiet week in the San Diego life sciences community, but local companies and organizations continue working away. —MEI Pharma, a late-stage cancer drug developer, presented updated data from a Phase 1b study of its lead drug candidate, ME-401, which is designed to inhibit a molecular pathway called PI3K delta.

article thumbnail

Back to the (Near) Future: Join Us for San Diego Life Sciences 2022

Xconomy

In 2010, Xconomy convened “San Diego Life Sciences 2030,” a séance with the soothsayers of San Diego as they gazed into the future at what the local life sciences landscape might look like 20 years from now. Read more » Reprints | Share:

article thumbnail

Acadia Looks to Expand Drug Beyond Parkinson’s Disease Psychosis

Xconomy

But the San Diego-based company has also been testing the drug in dementia-related psychosis (DRP), which includes those with Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease dementia, vascular dementia, and frontotemporal dementia patients who are experiencing hallucinations and delusions.

article thumbnail

As Alzheimer’s Conference Kicks Off, All Eyes Are on Biogen’s Drug

Xconomy

It’s the “era of neuroscience”; an industry “turning point”; and “an amazing time”—superlatives were flowing freely as the 11th annual Clinical Trials on Alzheimer’s Disease Congress (CTAD) kicked off in rainy San Diego late Wednesday afternoon.

article thumbnail

Retrophin Sinks as Drug “Pharma Bro” Martin Shkreli Co-Invented Fails

Xconomy

The San Diego-based company’s experimental drug fosmetpantotenate failed a Phase 3 trial, FORT, in patients with a rare and deadly neurological disorder called pantothenate kinase-associated neurodegeneration, or PKAN. Retrophin didn’t provide specifics; it’ll present the results at a future medical meeting.